• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The World Market for Anti-Infectives, Volume III – Antivirals

$2,500.00 – $5,000.00

Clear
SKU: KLI1077789 Categories: Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 136
  • Description
  • Table of Contents
  • Latest reports

Description

This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment:

  • Nucleoside Analogs
  • Protease Inhibitors
  • Other Misc. Antivirals

The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an

  • An overview
  • Description of products on the market
  • Description of products in development
  • Market estimates and forecasts through 2009
  • Market segmentation by infection type
  • Market segmentation by geographic region
  • Market share of leading suppliers
  • Market share of leading products

The report also includes statistical (epidemiologic and demographic) information for viral infections by type worldwide, with special emphasis on the United States and describes the major clinical, business, and regulatory trends shaping the global and domestic markets.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

Table of Contents

Chapter One: Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

Chapter Two: Introduction

  • Introduction to Viruses
    • Examples of Pathogenic Viruses
  • Virus Function and Life History
    • Replication in DNA Viruses
    • Replication of RNA Viruses
    • Replication in Retroviruses
  • Host Defenses Against Viruses
  • Viral Ploys to Invade Host Cells and Circumvent Host Responses
    • Invasion of Host Cells
    • Subversion of the Immune Response
    • Avoidance of Immune Detection and Attack by Killer Cells
  • HIV and AIDS
  • Demographics and Epidemiology
    • Cytomegalovirus
    • Hepatitis B Virus
    • Hepatitis C Virus (HCV)
    • Herpes
    • Human Immunodeficiency Virus (HIV)
    • Human Papillomavirus (HPV)
    • Influenza
    • Respiratory Syncytial Virus (RSV)
    • Population Demographics

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

  • Overview
  • Description of Products
    • Nucleoside Reverse Transcriptase Inhibitors
    • Zidovudine (Retrovir, GlaxoSmithKline)
    • Didanosine (Videx, Bristol-Myers Squibb)
    • Zalcitabine (Hivid, Roche)
    • Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
    • Stavudine (Zerit, Bristol-Myers Squibb)
    • Abacavir (Ziagen, GlaxoSmithKline)
    • Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Tenofovir (Viread, Gilead Sciences)
    • Adefovir dipivoxil (Hepsera, Gilead Sciences)
    • Combination Nucleoside Reverse Transcriptase Inhibitors
    • Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
    • Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
    • Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Nevirapine (Viramune, Boehringer Ingelheim)
    • Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
    • Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
    • Emtricitabine (Emtriva, Gilead Sciences)
    • DNA Polymerase Inhibitors
    • Acyclovir (Zovirax, GlaxoSmithKline)
    • Valacyclovir (Valtrex, GlaxoSmithKline)
    • Famciclovir (Famvir, Novartis)
    • Penciclovir (Denavir, Novartis)
    • Ganciclovir (Cytovene, Roche)
    • Ribavirin (Virazole, ICN Pharmaceuticals)
    • Foscarnet (Foscavir, AstraZeneca)
    • Valganciclovir (Valcyte, Hoffman-LaRoche)
    • Cidofovir (Vistide, Gilead Sciences)
  • Research and Development
    • Baraclude
    • Truvada
    • Telbivudine
    • Viramidine
    • Capravirine
    • Elvucitabine
    • Epzicom
    • Etravirine (TMC125)
    • GW5634
    • MIV 150
    • Pradefovir
    • Reverset
    • TMC278
    • Valopicitabine
    • Valtorcitabine
    • BILR 355
    • Calanolide A
    • DPC 961 and DPC 963
    • GW8248
    • MCC-478
    • MIV-310
  • Market Size and Growth
  • Competitive Analysis

Chapter Four: Protease Inhibitors

  • Overview
  • Description of Products
    • Single Agents
    • Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
    • Nelfinavir (Viracept, Agouron Pharmaceuticals)
    • Indinavir (Crixivan, Merck)
    • Ritonavir (Norvir, Abbott Laboratories)
    • Amprenavir (Agenerase, GlaxoSmithKline
    • Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
    • Atazanavir (Reyataz, Bristol-Myers Squibb)
    • Combination Protease Inhibitors
    • Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
  • Research and Development
    • Tipranavir (PNU-140690)
    • GW640385 (VX-385)
    • TMC-114
    • BMS232632
    • RO033-4649
    • VX-950
  • Market Size and Growth
  • Competitive Analysis

Chapter Five: Other Antivirals

  • Overview
  • Description of Products
    • Aldara
    • CytoGam
    • Flumadine
    • Fuzeon
    • Infergen
    • Pegasys
    • Pegasys + Copegus
    • Rebetol, Rebetron
    • Relenza
    • RespiGam
    • Symmetrel
    • Synagis
    • Tamiflu
    • Vistide
  • Research and Development
    • Attachment and Fusion Inhibitors
    • Gene Therapies
    • Integrase Inhibitors
    • Maturation Inhibitors
    • Zinc Finger Inhibitors
    • Antisense Drugs
    • Cytokines
    • Other
  • Market Size and Growth
  • Competitive Analysis

Chapter Six: Issues and Trends

  • Introduction
  • Antiviral Drug Resistance
  • HIV Drug Cost Controversy
  • Antiretroviral Treatment Regimens
  • HIV and Women
  • Global Surveillance
  • Biochemical Prevention and Treatment of Viral Infections
  • New Treatment for Hepatitis C
  • Costs and Funding of HIV Treatment
  • Access to HIV/AIDS Treatment

Chapter Seven: Total Market Size and Forecast

  • Overview
  • Total Market Size and Forecast

chapter Eight: Corporate Profiles

  • Introduction
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • MedImmune, Inc.
  • Merck & Company, Inc.
  • Novartis Pharmaceuticals Corporation
  • Roche
  • Schering-Plough Corporation

APPENDIX: Company Names and Addresses

List of Exhibits

Chapter One: Executive Summary

  • Table 7-1: The World Market for Antiviral Drugs 2002-2009
  • Figure 7-1: The World Market for Antiviral Drugs 2002-2009

Chapter Two: Introduction

  • Table 2-1: Host Cell Receptors
  • Table 2-1: Estimated World and U.S. Incidence of Viral Infections
  • Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
  • Table 2-2: World Population by Selected Geographical Region, 2004-2050
  • Figure 2-2: World Population by Selected Geographical Region, 2003-2050
  • Table 2-3: Estimated World Population by Age and Geographical Region, 2004
  • Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

  • Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
  • Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
  • Table 3-3: Currently Available DNA Polymerase Inhibitors
  • Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
  • Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
  • Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
  • Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
  • Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
  • Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
  • Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
  • Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
  • Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
  • Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
  • Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004

Chapter Four: Protease Inhibitors

  • Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
  • Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
  • Table 4-3: The Market for Protease Inhibitors 2002-2009
  • Figure 4-1: Protease Inhibitor Market 2002-2009
  • Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
  • Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
  • Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
  • Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
  • Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
  • Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004

Chapter Five: Other Antivirals

  • Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
  • Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
  • Table 5-3: The Market for Other Antivirals 2002-2009
  • Figure 5-1: The Market for Other Antivirals 2002-2009
  • Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
  • Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
  • Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
  • Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
  • Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
  • Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
  • Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
  • Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004

Chapter Six: Issues and Trends

  • Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
  • Table 6-2: Funding for HIV/AIDS
  • Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
  • Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World

Chapter Seven: Total Market Size and Forecast

  • Table 7-1: The World Market for Antiviral Drugs 2002-2009
  • Figure 7-1: The World Market for Antiviral Drugs 2002-2009
  • Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
  • Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003

    $795.00 – $1,590.00
  • Placeholder image

    Neurologic Cancers: Selections from “The World Market for Neurotherapeutic Drugs”

    $1,121.00 – $1,717.00
  • Placeholder image

    Type II Diabetes: The 45 Market in the United States for Drugs and Diagnostics

    $2,995.00 – $5,990.00
  • Placeholder image

    Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline

    $3,500.00 – $7,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Hispanics and Healthcare: Understanding Demographics, Health Statistics, and...The U.S Market for Over-the-Counter Cough, Cold, Allergy, and Sinus Medicat...
Scroll to top